Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In a previous study,
osteosarcoma
cells expressing both 5-lipoxygenase (5-LO) and 5
lipoxygenase
-activating protein (FLAP) synthesized leukotrienes upon A23187 stimulation (Dixon, R. A. F., R. E. Diehl, E. Opas, E. Rands, P. J. Vickers, J. F. Evans, J. W. Gillard, and D. K. Miller. 1990. Nature (Lond.). 343:282-284).
Osteosarcoma
cells expressing 5-LO but not expressing FLAP were unable to synthesize leukotrienes. Thus, it was determined that FLAP was required for the cellular synthesis of leukotrienes. To examine the role of FLAP in A23187-induced translocation of 5-LO to a membrane fraction, we have studied the A23187-stimulated translocation of 5-LO in
osteosarcoma
cells expressing both 5-LO and FLAP, and in
osteosarcoma
cells expressing 5-LO only. We demonstrate that in cells expressing both 5-LO and FLAP, 5-LO translocates to membranes in response to A23187 stimulation. This 5-LO translocation is inhibited when cells are stimulated in the presence of MK-886. In
osteosarcoma
cells expressing 5-LO but not expressing FLAP, 5-LO is able to associate with membranes following A23187 stimulation. In contrast to the cells containing both 5-LO and FLAP, MK-886 is unable to prevent 5-LO membrane association in cells transfected with 5-LO alone. Therefore, we have demonstrated that in this cell system, 5-LO membrane association and activation can be separated into at least two distinct steps: (1) calcium-dependent movement of 5-LO to membranes without product formation, which can occur in the absence of FLAP (membrane association), and (2) activation of 5-LO with product formation, which is FLAP dependent and inhibited by MK-886 (enzyme activation).
...
PMID:A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells. 146 57
Leukotriene B4 (LTB4) is an arachidonic acid
lipoxygenase
metabolite with well-characterized effects on leukocytes. LTB4 has been implicated in acute inflammatory reactions and in bone resorption. In the present study, the effect of LTB4 on osteoblastic cells was examined. LTB4 inhibited cell proliferation in normal osteoblastic rat calvaria cells in a dose-dependent manner and had biphasic effects in the human osteoblast-like
osteosarcoma
cell lines Saos-2 and G292. Indomethacin did not modulate the nature of these LTB4 effects in any of the cells. However, it potentiated the high LTB4 dose effects in normal cells and G292 cells. AA861, an inhibitor of
lipoxygenase
, did not modulate the LTB4 effects in these two cell lines. These results suggest that LTB4 is involved in the regulation of osteoblastic cell proliferation and may interact with prostaglandins to modulate these effects.
...
PMID:Effects of leukotrienes on osteoblastic cell proliferation. 165 27
The metabolites of cycloxyegenase and
lipoxygenase
pathways are known to play an important role in the bone metabolism involving osteoclast and osteoblast interaction, bone resorption and morphogenesis. The recently discovered growth factor TGF-beta is abundant in bone and some of its intracellular and extracellular effects depend on de novo synthesis of eicosanoids. However, the effect of TGF-beta on the synthesis and the release of eicosanoid by bone cells is essentially unknown. In the present study we have identified the main eicosanoid metabolites produced by osteogenic
osteosarcoma
cell-line SAOS1 and investigated how production and release of these is affected by TGF-beta. We found that the leukotriene C4 is the main metabolite produced by these cells and that TGF-beta induces concentration-dependent, quantitative and qualitative alterations in eicosanoid production and release by human osteogenic
osteosarcoma
cells SAOS1.
...
PMID:Transforming growth factor-beta modulates eicosanoid metabolism in osteogenic osteosarcoma cells. 190 41
Cloned 15-lipoxygenase has been expressed for the first time in eukaryotic and prokaryotic cells. Transfection of
osteosarcoma
cells with a mammalian expression plasmid containing the cDNA for human reticulocyte 15-lipoxygenase resulted in cell lines that were capable of oxidizing body arachidonic acid and linoleic acid. The
lipoxygenase
metabolites were identified by reverse-phase and straight-phase high pressure liquid chromatography, ultraviolet spectroscopy, and direct mass spectrometry, verifying that the cDNA for 15-lipoxygenase encodes an enzyme with authentic 15-lipoxygenase activity. Incubation of the transformed cells with arachidonic acid generated 15-hydroxyeicosatetraenoic acid (HETE) and 12-HETE in a ratio of 8.6 to 1, demonstrating that 15-lipoxygenase can also perform 12-lipoxygenation. Lesser amounts of 15-keto-ETE, four isomers of 8,15-diHETE, and one isomer of 14,15-diHETE were observed. Incubation with linoleic acid generated predominantly 13-hydroxy linoleic acid. The reaction was inhibited by eicosatetraynoic acid but not by indomethacin. Antibodies to a peptide corresponding to a unique region of the predicted amino acid sequence were generated and shown to react with one major band of 70 kDa on immunoblots of human leukocyte 15-lipoxygenase. To obtain antibodies to the full length enzyme, the cDNA was subcloned into a bacterial expression vector and was expressed as a fusion with the CheY protein. The overexpressed protein was readily purified from bacteria and was shown to be immunoreactive to the peptide-derived antibody. Antibodies raised to this recombinant enzyme did not cross-react with human leukocyte 5-lipoxygenase but did identify 15-lipoxygenase in rabbit reticulocytes, human leukocytes, and tracheal epithelial cells, suggesting that the 15-lipoxygenases from these different cell types are structurally related.
...
PMID:Expression of cloned human reticulocyte 15-lipoxygenase and immunological evidence that 15-lipoxygenases of different cell types are related. 231 85
Amine-carboxyboranes have been shown to prevent osteoporosis and loss of bone mass in rodents. In vitro studies using CF1 mouse pup calvaria and rat UMR-106
osteosarcoma
cells showed that amine-carboxyborane derivatives reduced significantly the loss of intracellular calcium into the growth medium from 10(-4) to 10(-8) M over 48 hours. Amine-carboxyborane derivatives were more effective than calcitonin or simple boron salts. Calcium incorporation into these cells and proline incorporation into collagen was accelerated in the presence of amine carboxyboranes. The amine-carboxyborane derivatives effectively inhibited lysosomal and proteolytic enzymes as well as activities of serine elastase, prostaglandin cyclooxygenase, and 5'-
lipoxygenase
in mouse macrophages, human PMNs, leukocytes and Be Sal cells. IC50 values were in the range of 10(-6) M. In lactating ovariectomized female rats after administered amine-carboxyboranes for 14 days at 8 mg/kg/day orally, the femur and humerus showed increased volume, weight, density and ash weight. Serum calcium levels were elevated significantly with minimum reductions on serum inorganic phosphate levels. Femur calcium levels were elevated after treatment with amine-carboxyborane derivatives, but not with etidronate. Humerus total lipids after 14 days were slightly elevated probably due to increased levels of triglycerides and phospholipids.
...
PMID:The anti-osteoporotic activity of amine-carboxyboranes in rodents. 764 84
The effects of interleukin-1 alpha (IL-1 alpha) on arachidonic acid (AA) metabolism were studied in the human
osteosarcoma
cell lines, G292 and SaOS-2. The cells were prelabeled with 3H-arachidonic acid. Radiolabeled metabolites were measured by reversed-phase high-pressure liquid chromatography with a radioactive detector. Indomethacin inhibited prostaglandin E2 (PGE2) production without affecting
lipoxygenase
(LO) products in G292 cells. In the G292 cells, IL-1 alpha (50 U/ml) induced a 10-fold increase in PGE2 production at all the incubation times tested, and a significant two-fold increase in 5 hydroxyeicosatetraenoic acid (HETE) formation after 48 h. These effects were not seen in SaOS-2 cells under identical conditions. These results suggest that, although some osteosarcomal cell lines may not respond directly to IL-1 with effects on AA metabolism, the mechanism of its action in others may involve modulation of both cyclooxygenase (CO) and LO pathways.
...
PMID:Effects of interleukin-1 alpha on arachidonic acid metabolism in human osteosarcoma osteoblastic cells. 839 96
The induced differentiation of tumor cells into mature phenotypes is a promising strategy in cancer therapy. In this study, the effects of combined treatment with all-trans retinoic acid (ATRA) and
lipoxygenase
/cyclooxygenase inhibitors were examined in two
osteosarcoma
cell lines, Saos-2 and OSA-01. Caffeic acid and celecoxib were used as inhibitors of 5-lipoxygenase and of cyclooxygenase-2, respectively. Changes in the cell proliferation, matrix mineralization, and occurrence of differentiation markers were evaluated in treated cell populations at intervals. The results confirmed the capability of caffeic acid to enhance the antiproliferative effect of ATRA in both cell lines. In contrast, celecoxib showed the same effect in Saos-2 cells only. Furthermore, the extension of matrix mineralization was observed after combined treatment with ATRA and celecoxib or caffeic acid. The increased expression of osteogenic differentiation markers was observed in both cell lines after the combined application of ATRA and inhibitors. The obtained results clearly demonstrate the capability of
lipoxygenase
/cyclooxygenase inhibitors to enhance the antiproliferative and differentiating effect of ATRA in
osteosarcoma
cells, although some of these effects are specific and depend on the biological features of the respective tumor or cell line.
...
PMID:LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines. 2479 77